Endometrial Cancer Pipeline Analysis Report 2026

Report Coverage

The Endometrial Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into endometrial cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for endometrial cancer. The endometrial cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The endometrial cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with endometrial cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to endometrial cancer.

Read more about this report - Request a Free Sample

Endometrial Cancer Pipeline Outlook

Endometrial cancer is a malignancy originating in the endometrium, the inner lining of the uterus. It typically develops due to prolonged estrogen exposure unopposed by progesterone, genetic mutations, or metabolic risk factors such as obesity. Abnormal cellular proliferation leads to tumor formation, commonly presenting with postmenopausal bleeding and pelvic discomfort.

Endometrial cancer treatment involves surgery, primarily hysterectomy with bilateral salpingo-oophorectomy, followed by risk-adapted radiotherapy or chemotherapy. Advanced or recurrent disease may require targeted therapy, immunotherapy, or hormone therapy based on molecular profiling and disease stage. In June 2024, the U.S. Food and Drug Administration approved pembrolizumab with carboplatin and paclitaxel for primary advanced or recurrent endometrial carcinoma, followed by maintenance pembrolizumab. Developed by Merck, the regimen demonstrated significant progression-free survival improvement in mismatch repair–deficient and proficient patient cohorts in the KEYNOTE-868 trial.

Endometrial Cancer Epidemiology

The pipeline has strong growth potential driven by rising disease incidence and evolving therapeutic strategies. According to Songkun Gao et al., 2025, incidence among postmenopausal women aged 55 years and above is projected to increase by 6.5% by 2036, despite an 8.0% decline in mortality. As per Jason D. Wright et al., 2025, uterine cancer incidence in the United States may reach 74.2 per 100,000 in White women and 86.9 per 100,000 in Black women by 2050. Additionally, according to Health Data Insight, the United Kingdom reports over 9,700 new cases annually, supporting continued pipeline innovation and targeted drug development demand.

Endometrial Cancer – Pipeline Therapeutic Assessment

Endometrial Cancer Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 49%, covers a major share of the total endometrial cancer clinical trials, reflecting strong mid-stage clinical advancement and commercialization potential. Phase I at 37% and phase III at 11% indicate sustained innovation and late-stage progression. This balanced progression supports therapeutic advancements, regulatory approvals, and overall market expansion.

Endometrial Cancer Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the endometrial cancer pipeline analysis include small molecules, monoclonal antibodies, and natural metabolites. The endometrial cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for endometrial cancer. HER2-targeted antibody–drug conjugates are emerging as promising options for endometrial cancer management. For instance, trastuzumab deruxtecan is being investigated in the Phase 3 DESTINY-Endometrial01 trial in combination with immune checkpoint inhibitors such as pembrolizumab or rilvegostomig. It selectively binds to HER2-expressing tumor cells and delivers a cytotoxic topoisomerase I inhibitor payload, thereby enhancing antitumor activity and improving therapeutic outcomes.

Endometrial Cancer Clinical Trials – Key Players

The EMR report for the endometrial cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed endometrial cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in endometrial cancer clinical trials:

• BioNTech SE
• SystImmune Inc.
• DualityBio Inc.
• Evergreen Therapeutics, Inc.
• BioMimetix JV, LLC
• Sichuan Baili Pharmaceutical Co., Ltd.
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Iovance Biotherapeutics, Inc.

Endometrial Cancer – Emerging Drugs Profile

Key Questions Answered in the Endometrial Cancer Pipeline Insight Report

• Which companies/institutions are leading the endometrial cancer drug development?
• Which company is leading the endometrial cancer pipeline development activities?
• What is the current endometrial cancer commercial assessment?
• What are the opportunities and challenges present in the endometrial cancer pipeline landscape?
• What is the efficacy and safety profile of endometrial cancer pipeline drugs?
• Which company is conducting major trials for endometrial cancer drugs?
• Which companies/institutions are involved in endometrial cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in endometrial cancer?

Reasons To Buy This Report

The Endometrial Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for endometrial cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into endometrial cancer collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Cancer Supportive Care Drugs Market

Cancer Therapeutics Market

Cancer Screening Market